JAMA- Coronavirus Vaccine FDA Update

Angie SzumlinskiHealth

The JAMA Network recently released a new video to their Q&A series that discussed the Pfizer/BioNTech and Moderna Covid-19 vaccines. Topics included:

  • Pfizer EUA application
  • Differences in EUAs for vaccines vs drugs
  • Surprises in data
  • Post-authorization safety surveillance
  • Unknowns: duration of protection, asymptomatic transmission, virus mutation
  • How vaccines can reduce non-COVID-19 excess deaths
  • Patients with allergies
  • Bell’s Palsy
  • FDA role in vaccine manufacture and distribution
  • Length of immunity, asymptomatic transmission, virus mutation
  • Political interference

Check out the full video for lots of great information, and explore their YouTube channel for more Covid-19 updates and information.

Coronavirus Vaccine FDA Update – December 14, 2020

Peter W. Marks, MD, PhD and Stephen M. Hahn, MD return to JAMA’s Q&A series to discuss the Pfizer/BioNTech and Moderna vaccines: the data, the weekend’s EUA designation (Pfizer/BioNTech), and the process for future full licensure and postmarketing safety surveillance. Dr. Marks directs the US FDA’s Center for Biologics Evaluation and Research (CBER).